| scholarly article | Q13442814 |
| P2093 | author name string | Mitchell S Cairo | |
| Yanling Liao | |||
| Prakash Lingasamy | |||
| Olli Ritvos | |||
| Tero A H Järvinen | |||
| Tambet Teesalu | |||
| Ulrike May | |||
| Shreya Makkapati | |||
| Larisa Ivanova | |||
| Allan Tobi | |||
| Stuart Prince | |||
| Toini Pemmari | |||
| Anja Pasternack | |||
| P2860 | cites work | Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta | Q24321274 |
| Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition | Q26772197 | ||
| Vascular zip codes in angiogenesis and metastasis | Q31064524 | ||
| Age-related changes in the proteoglycans of human skin. Specific cleavage of decorin to yield a major catabolic fragment in adult skin | Q31134336 | ||
| Molecular changes in the vasculature of injured tissues | Q33289271 | ||
| C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration | Q33508760 | ||
| Targeting of drugs and nanoparticles to tumors | Q33751710 | ||
| Role of carbonic anhydrases in skin wound healing | Q33754072 | ||
| Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs | Q33897492 | ||
| Design of target-seeking antifibrotic compounds | Q34262398 | ||
| Nanoparticle-induced vascular blockade in human prostate cancer | Q34282277 | ||
| Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice | Q34411532 | ||
| Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels | Q34439113 | ||
| Tissue-penetrating delivery of compounds and nanoparticles into tumors | Q35016106 | ||
| Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging | Q35047373 | ||
| Peptide-directed highly selective targeting of pulmonary arterial hypertension | Q35070520 | ||
| Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity | Q35085132 | ||
| The role of decorin in collagen fibrillogenesis and skin homeostasis | Q35219612 | ||
| Transforming growth factor-beta in disease: the dark side of tissue repair | Q35603155 | ||
| Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring | Q35843492 | ||
| Tumor penetrating peptides for improved drug delivery | Q35978545 | ||
| Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms | Q36057596 | ||
| Decorin: a guardian from the matrix | Q36131541 | ||
| Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility | Q36258506 | ||
| An antimetastatic role for decorin in breast cancer. | Q36855729 | ||
| Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases | Q37245959 | ||
| Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. | Q37712686 | ||
| Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery | Q37723654 | ||
| Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. | Q37743873 | ||
| β-catenin signaling: a novel mediator of fibrosis and potential therapeutic target | Q37925433 | ||
| Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC. | Q38383977 | ||
| Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. | Q38969810 | ||
| Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa | Q39044711 | ||
| Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa | Q39275579 | ||
| Transtumoral targeting enabled by a novel neuropilin-binding peptide. | Q39426043 | ||
| SDF-1/54-DCN: a novel recombinant chimera with dual inhibitory effects on proliferation and chemotaxis of tumor cells | Q39976130 | ||
| Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation | Q40256606 | ||
| Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation | Q40429853 | ||
| Differential interactions of decorin and decorin mutants with type I and type VI collagens | Q40529043 | ||
| Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation | Q40581730 | ||
| Light and X-ray scattering show decorin to be a dimer in solution. | Q40668731 | ||
| Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease | Q41078715 | ||
| A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension | Q41882126 | ||
| Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity | Q46149384 | ||
| Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha2beta1 integrin activity | Q46644000 | ||
| Therapies for genetic extracellular matrix diseases of the skin | Q47253771 | ||
| Granzyme B in skin inflammation and disease | Q47286407 | ||
| Injury- and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa. | Q47698536 | ||
| Progress in Epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. | Q53105158 | ||
| TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa. | Q54343728 | ||
| Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier. | Q54915254 | ||
| Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction. | Q55428949 | ||
| Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa | Q64042158 | ||
| A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa | Q72691286 | ||
| Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model | Q88625907 | ||
| Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin | Q88920582 | ||
| Systemically Administered, Target-Specific, Multi-Functional Therapeutic Recombinant Proteins in Regenerative Medicine | Q89510783 | ||
| Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study | Q91054485 | ||
| Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies | Q91273591 | ||
| Cord Blood-Derived Stem Cells Suppress Fibrosis and May Prevent Malignant Progression in Recessive Dystrophic Epidermolysis Bullosa | Q91684222 | ||
| Toward treatment and cure of epidermolysis bullosa | Q91889778 | ||
| R-Ras regulates vascular permeability, but not overall healing in skin wounds | Q93390947 | ||
| P921 | main subject | epidermolysis bullosa | Q923020 |
| P577 | publication date | 2020-05-20 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa |
Search more.